董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dennis H. Langer | 男 | Independent Director | 74 | 15.76万美元 | 11.50 | 2026-08-20 |
| Michael Myers | 男 | Chairman of the Board,Chief Executive Officer and Director | 64 | 150.73万美元 | 9.29 | 2026-08-20 |
| Denise Carter | 女 | Chief Operating Officer and Director | 57 | 128.23万美元 | 9.29 | 2026-08-20 |
| Joseph Cooper | 男 | Independent Director | 68 | 17.00万美元 | 0.20 | 2026-08-20 |
| Natalie Leong | 女 | Independent Director | 41 | 17.48万美元 | 0.28 | 2026-08-20 |
| Michael Sember | 男 | Independent Director | 76 | 16.50万美元 | 0.20 | 2026-08-20 |
| James Culverwell | 男 | Independent Director | 69 | 16.26万美元 | 5.39 | 2026-08-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sally Lawlor | 女 | Chief Financial Officer | 43 | 未披露 | 未持股 | 2026-08-20 |
| Michael Myers | 男 | Chairman of the Board,Chief Executive Officer and Director | 64 | 150.73万美元 | 9.29 | 2026-08-20 |
| Denise Carter | 女 | Chief Operating Officer and Director | 57 | 128.23万美元 | 9.29 | 2026-08-20 |
董事简历
中英对照 | 中文 | 英文- Dennis H. Langer
-
Dennis H. Langer，自2019年起担任Quoin Inc.的董事。Langer博士自2021年10月28日起担任Quoin Ltd.的董事。从2005年到2010年，Langer博士担任Phoenix IP Ventures，LLC的管理合伙人，Phoenix IP Ventures，LLC是一家专注于生命科学公司的私募股权和风险投资基金。2004年至2005年，Langer博士担任跨国制药公司Dr. Reddy's Laboratories，Inc.的北美地区总裁。Langer博士于1994年至2004年在跨国制药和生物技术公司葛兰素史克任职，曾担任项目、投资组合和联盟管理高级副总裁、产品开发战略高级副总裁和医疗保健服务研发高级副总裁。1991年至1994年，他在临床阶段生物制药公司Neose Technologies，Inc.担任总裁兼首席执行官。2004年至2022年6月，Langer博士担任Myriad Genetics, Inc.的董事，Myriad Genetics, Inc.是一家上市公司，也是一家基因检测和精准医疗公司。2021年至2022年6月，Langer博士担任Brooklyn ImmunoTherapeutics，Inc.（n/k/a Eterna Therapeutics Inc.）的董事，Brooklyn ImmunoTherapeutics，Inc.是一家上市公司，也是一家生物技术公司。2007年至2019年，Langer博士担任Dicerna Pharmaceuticals Inc.的董事，Dicerna Pharmaceuticals Inc.是一家上市公司和生物制药公司。Langer博士自2010年起担任哈佛法学院院长顾问委员会成员，自2020年起担任Whitehead Institute研究所所长。他获得了乔治城大学医学院的医学博士学位、哈佛大学法学院的法学博士学位、哥伦比亚大学的生物学学士学位。
Dennis H. Langer has served as a director of Quoin Inc. since 2019. Dr. Langer has served as a director of Quoin Ltd. since October 28, 2021. From 2005 to 2010, Dr. Langer served as a Managing Partner at Phoenix IP Ventures, LLC, a private equity and venture capital fund specializing in life sciences companies. From 2005 to 2010, Dr. Langer was also a Co Founder and Director of Ception Therapeutics, Inc., until its acquisition by Cephalon, Inc. From 2004 to 2005, Dr. Langer was the President, North America for Dr. Reddy's Laboratories, Inc., a multi national pharmaceutical company. Dr. Langer was with GlaxoSmithKline, a multi national pharmaceutical and biotechnology company, from 1994 – 2004, where he served as Senior Vice President, Project, Portfolio and Alliance Management, Senior Vice President, Product Development Strategy, and Senior Vice President, Healthcare Services R&D. From 1991 to 1994, he served as President and Chief Executive Officer at Neose Technologies, Inc., a clinical stage biopharmaceutical company. From 2004 to June 2022, Dr. Langer served as a director of Myriad Genetics, Inc., a publicly traded company and a genetic testing and precision medicine company. From 2021 to June 2022, Dr. Langer served as a director of Brooklyn ImmunoTherapeutics, Inc. (n/k/a Eterna Therapeutics Inc.), a publicly traded company and a biotechnology company. From 2007 to 2019, Dr. Langer served as a director of Dicerna Pharmaceuticals Inc., a publicly traded company and a biopharmaceutical company. From 2005 to 2006, Dr. Langer served as a Director of Sirna Therapeutics, Inc., a publicly traded company and biopharmaceutical company, until its acquisition by Merck and Co., Inc. Dr. Langer has served on the Dean's Advisory Board of Harvard Law School since 2010, and as a Member of the Health Sciences Board of Advisors at Georgetown University since 2025. He received an M.D. from Georgetown University School of Medicine, a J.D. from Harvard Law School, and a B.A. in Biology from Columbia University. - Dennis H. Langer，自2019年起担任Quoin Inc.的董事。Langer博士自2021年10月28日起担任Quoin Ltd.的董事。从2005年到2010年，Langer博士担任Phoenix IP Ventures，LLC的管理合伙人，Phoenix IP Ventures，LLC是一家专注于生命科学公司的私募股权和风险投资基金。2004年至2005年，Langer博士担任跨国制药公司Dr. Reddy's Laboratories，Inc.的北美地区总裁。Langer博士于1994年至2004年在跨国制药和生物技术公司葛兰素史克任职，曾担任项目、投资组合和联盟管理高级副总裁、产品开发战略高级副总裁和医疗保健服务研发高级副总裁。1991年至1994年，他在临床阶段生物制药公司Neose Technologies，Inc.担任总裁兼首席执行官。2004年至2022年6月，Langer博士担任Myriad Genetics, Inc.的董事，Myriad Genetics, Inc.是一家上市公司，也是一家基因检测和精准医疗公司。2021年至2022年6月，Langer博士担任Brooklyn ImmunoTherapeutics，Inc.（n/k/a Eterna Therapeutics Inc.）的董事，Brooklyn ImmunoTherapeutics，Inc.是一家上市公司，也是一家生物技术公司。2007年至2019年，Langer博士担任Dicerna Pharmaceuticals Inc.的董事，Dicerna Pharmaceuticals Inc.是一家上市公司和生物制药公司。Langer博士自2010年起担任哈佛法学院院长顾问委员会成员，自2020年起担任Whitehead Institute研究所所长。他获得了乔治城大学医学院的医学博士学位、哈佛大学法学院的法学博士学位、哥伦比亚大学的生物学学士学位。
- Dennis H. Langer has served as a director of Quoin Inc. since 2019. Dr. Langer has served as a director of Quoin Ltd. since October 28, 2021. From 2005 to 2010, Dr. Langer served as a Managing Partner at Phoenix IP Ventures, LLC, a private equity and venture capital fund specializing in life sciences companies. From 2005 to 2010, Dr. Langer was also a Co Founder and Director of Ception Therapeutics, Inc., until its acquisition by Cephalon, Inc. From 2004 to 2005, Dr. Langer was the President, North America for Dr. Reddy's Laboratories, Inc., a multi national pharmaceutical company. Dr. Langer was with GlaxoSmithKline, a multi national pharmaceutical and biotechnology company, from 1994 – 2004, where he served as Senior Vice President, Project, Portfolio and Alliance Management, Senior Vice President, Product Development Strategy, and Senior Vice President, Healthcare Services R&D. From 1991 to 1994, he served as President and Chief Executive Officer at Neose Technologies, Inc., a clinical stage biopharmaceutical company. From 2004 to June 2022, Dr. Langer served as a director of Myriad Genetics, Inc., a publicly traded company and a genetic testing and precision medicine company. From 2021 to June 2022, Dr. Langer served as a director of Brooklyn ImmunoTherapeutics, Inc. (n/k/a Eterna Therapeutics Inc.), a publicly traded company and a biotechnology company. From 2007 to 2019, Dr. Langer served as a director of Dicerna Pharmaceuticals Inc., a publicly traded company and a biopharmaceutical company. From 2005 to 2006, Dr. Langer served as a Director of Sirna Therapeutics, Inc., a publicly traded company and biopharmaceutical company, until its acquisition by Merck and Co., Inc. Dr. Langer has served on the Dean's Advisory Board of Harvard Law School since 2010, and as a Member of the Health Sciences Board of Advisors at Georgetown University since 2025. He received an M.D. from Georgetown University School of Medicine, a J.D. from Harvard Law School, and a B.A. in Biology from Columbia University.
- Michael Myers
-
Michael Myers是特拉华州公司、Quoin Ltd（简称“Quoin Inc.”）的全资子公司Quoin制药的联合创始人，自Quoin Inc.于2018年成立以来一直担任该公司的董事长兼首席执行官。Myers博士自2021年10月28日起担任Quoin Ltd.董事长兼首席执行官。Myers博士在药物输送和专业制药领域拥有超过35年的行业经验。2003年至2015年10月，他担任生物治疗制药公司Innocoll AG（n/k/a Innocoll Biotherapeutics N.A. Inc.）的首席执行官，并负责该公司于2014年上市。2001年至2002年，他担任West Pharmaceutical Services, Inc.（纽约证券交易所代码：WST）药物输送部门的总裁，该公司是注射药物包装和输送系统的设计者和制造商。从1996年到1999年，迈尔斯博士担任食品和药物输送系统和技术开发商Fuisz Technologies（Biovail）的制药业务总裁。2000年至2001年，迈尔斯博士担任Flamel Technologies（n/k/a Avadel制药 PLC（纳斯达克：AVDL））的执行副总裁兼首席商务官，这是一家专业制药公司。从1987年到1995年，迈尔斯博士担任生物技术制药公司Elan公司的药物开发主管。从2022年到2023年6月，迈尔斯博士担任Ethicann Pharmaceuticals和SquareX Pharmaceuticals的董事，这两家公司都是一家处于临床阶段的制药公司。2023年8月，迈尔斯博士成为临床前阶段医疗设备公司Cranial Devices Inc.的董事。自2019年以来，迈尔斯博士一直担任Sonoran Bioscience和Wellesley Pharmaceuticals的董事，这两家公司都是一家专业制药公司。迈尔斯博士在爱尔兰科克大学学院获得化学博士学位。
Michael Myers is the co founder of Quoin Inc. and has served as Chairman and Chief Executive Officer of Quoin Pharmaceuticals, Inc. ("Quoin Inc.") since its inception in 2018. Dr. Myers has served as Chairman and Chief Executive Officer of Quoin Ltd. since October 28, 2021. Dr. Myers has over 36 years of industry experience in the drug delivery and specialty pharmaceutical sectors. From 2003 to October 2015, he served as Chief Executive Officer of Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), a biotherapeutics pharmaceutical company, and was responsible for taking that company public in 2014. From 2001 to 2002, he served as President of the drug delivery division of West Pharmaceutical Services, Inc., a publicly traded company and a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. From 1996 to 1999, Dr. Myers served as the President of Pharmaceutical Operations for Fuisz Technologies (Biovail), a developer of food and drug delivery systems and technologies. From 2000 to 2001, Dr. Myers served as Executive Vice President and Chief Commercial Officer of Flamel Technologies (n/k/a Avadel Pharmaceuticals PLC, a publicly traded company and a specialty pharmaceutical company). From 1987 to 1995, Dr. Myers served as the Head of Pharmaceutical Development for Elan Corporation, a biotechnology drug company. Since 2019, Dr. Myers has served as a director of Sonoran Bioscience and Wellesley Pharmaceuticals, each a specialty pharmaceutical company. Dr. Myers has served as a director of Cranial Devices, a clinical stage medical device company since 2023. Dr. Myers earned his Ph.D. in Chemistry from University College Cork, Ireland. - Michael Myers是特拉华州公司、Quoin Ltd（简称“Quoin Inc.”）的全资子公司Quoin制药的联合创始人，自Quoin Inc.于2018年成立以来一直担任该公司的董事长兼首席执行官。Myers博士自2021年10月28日起担任Quoin Ltd.董事长兼首席执行官。Myers博士在药物输送和专业制药领域拥有超过35年的行业经验。2003年至2015年10月，他担任生物治疗制药公司Innocoll AG（n/k/a Innocoll Biotherapeutics N.A. Inc.）的首席执行官，并负责该公司于2014年上市。2001年至2002年，他担任West Pharmaceutical Services, Inc.（纽约证券交易所代码：WST）药物输送部门的总裁，该公司是注射药物包装和输送系统的设计者和制造商。从1996年到1999年，迈尔斯博士担任食品和药物输送系统和技术开发商Fuisz Technologies（Biovail）的制药业务总裁。2000年至2001年，迈尔斯博士担任Flamel Technologies（n/k/a Avadel制药 PLC（纳斯达克：AVDL））的执行副总裁兼首席商务官，这是一家专业制药公司。从1987年到1995年，迈尔斯博士担任生物技术制药公司Elan公司的药物开发主管。从2022年到2023年6月，迈尔斯博士担任Ethicann Pharmaceuticals和SquareX Pharmaceuticals的董事，这两家公司都是一家处于临床阶段的制药公司。2023年8月，迈尔斯博士成为临床前阶段医疗设备公司Cranial Devices Inc.的董事。自2019年以来，迈尔斯博士一直担任Sonoran Bioscience和Wellesley Pharmaceuticals的董事，这两家公司都是一家专业制药公司。迈尔斯博士在爱尔兰科克大学学院获得化学博士学位。
- Michael Myers is the co founder of Quoin Inc. and has served as Chairman and Chief Executive Officer of Quoin Pharmaceuticals, Inc. ("Quoin Inc.") since its inception in 2018. Dr. Myers has served as Chairman and Chief Executive Officer of Quoin Ltd. since October 28, 2021. Dr. Myers has over 36 years of industry experience in the drug delivery and specialty pharmaceutical sectors. From 2003 to October 2015, he served as Chief Executive Officer of Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), a biotherapeutics pharmaceutical company, and was responsible for taking that company public in 2014. From 2001 to 2002, he served as President of the drug delivery division of West Pharmaceutical Services, Inc., a publicly traded company and a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. From 1996 to 1999, Dr. Myers served as the President of Pharmaceutical Operations for Fuisz Technologies (Biovail), a developer of food and drug delivery systems and technologies. From 2000 to 2001, Dr. Myers served as Executive Vice President and Chief Commercial Officer of Flamel Technologies (n/k/a Avadel Pharmaceuticals PLC, a publicly traded company and a specialty pharmaceutical company). From 1987 to 1995, Dr. Myers served as the Head of Pharmaceutical Development for Elan Corporation, a biotechnology drug company. Since 2019, Dr. Myers has served as a director of Sonoran Bioscience and Wellesley Pharmaceuticals, each a specialty pharmaceutical company. Dr. Myers has served as a director of Cranial Devices, a clinical stage medical device company since 2023. Dr. Myers earned his Ph.D. in Chemistry from University College Cork, Ireland.
- Denise Carter
-
Denise Carter是Quoin Inc.的联合创始人，自2018年成立以来一直担任Quoin Inc.的董事和首席运营官。卡特女士自2021年10月28日起担任Quoin Ltd.的董事和首席运营官。Denise Carter女士在药物输送和专业制药行业拥有超过30年的经验。2003年6月至2015年10月，Carter女士在Innocoll AG（n/k/a Innocoll Biotherapeutics N.A. Inc.）担任多个职位，包括Innocoll Pharmaceuticals总裁和Innocoll AG业务发展和公司事务执行副总裁。2001年至2003年，卡特女士担任西药公司（纽约证券交易所代码：WST）药物输送部门的业务发展副总裁。2000年至2001年，她担任专业制药公司Eurand的业务发展高级总监。1996年至1999年，卡特女士担任Fuisz Technologies（Biovail）业务发展和联盟管理总监。1999年至2000年，卡特女士担任卡地纳健康集团业务发展总监，这是一家跨国医疗保健服务公司。卡特在宾夕法尼亚大学沃顿商学院获得MBA学位，在威廉玛丽学院获得化学学士学位。
Denise Carter is the co founder of Quoin Inc. and has served as a director and Chief Operating Officer of Quoin Inc. since its inception in 2018. Ms. Carter has served as a director and Chief Operating Officer of Quoin Ltd. since October 28, 2021. Ms. Denise Carter has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. From June 2003 to October 2015, Ms. Carter held various positions at Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), including President of Innocoll Pharmaceuticals and Executive Vice President of Business Development and Corporate Affairs of Innocoll AG. From 2001 to 2003, Ms. Carter was the Vice President of Business Development of the drug delivery division of West Pharmaceuticals, Inc., a publicly traded company. From 2000 to 2001, she was the Senior Director of Business Development of Eurand, a specialty pharmaceutical company. From 1996 to 1999, Ms. Carter was the Director of Business Development and Alliance Management of Fuisz Technologies (Biovail). From 1999 to 2000, Ms. Carter was the Director of Business Development of Cardinal Health, Inc., a multi national health care service company. Ms. Carter earned her MBA from Wharton School of Business, University of Pennsylvania and a B.S. in Chemistry from the College of William and Mary. - Denise Carter是Quoin Inc.的联合创始人，自2018年成立以来一直担任Quoin Inc.的董事和首席运营官。卡特女士自2021年10月28日起担任Quoin Ltd.的董事和首席运营官。Denise Carter女士在药物输送和专业制药行业拥有超过30年的经验。2003年6月至2015年10月，Carter女士在Innocoll AG（n/k/a Innocoll Biotherapeutics N.A. Inc.）担任多个职位，包括Innocoll Pharmaceuticals总裁和Innocoll AG业务发展和公司事务执行副总裁。2001年至2003年，卡特女士担任西药公司（纽约证券交易所代码：WST）药物输送部门的业务发展副总裁。2000年至2001年，她担任专业制药公司Eurand的业务发展高级总监。1996年至1999年，卡特女士担任Fuisz Technologies（Biovail）业务发展和联盟管理总监。1999年至2000年，卡特女士担任卡地纳健康集团业务发展总监，这是一家跨国医疗保健服务公司。卡特在宾夕法尼亚大学沃顿商学院获得MBA学位，在威廉玛丽学院获得化学学士学位。
- Denise Carter is the co founder of Quoin Inc. and has served as a director and Chief Operating Officer of Quoin Inc. since its inception in 2018. Ms. Carter has served as a director and Chief Operating Officer of Quoin Ltd. since October 28, 2021. Ms. Denise Carter has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. From June 2003 to October 2015, Ms. Carter held various positions at Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), including President of Innocoll Pharmaceuticals and Executive Vice President of Business Development and Corporate Affairs of Innocoll AG. From 2001 to 2003, Ms. Carter was the Vice President of Business Development of the drug delivery division of West Pharmaceuticals, Inc., a publicly traded company. From 2000 to 2001, she was the Senior Director of Business Development of Eurand, a specialty pharmaceutical company. From 1996 to 1999, Ms. Carter was the Director of Business Development and Alliance Management of Fuisz Technologies (Biovail). From 1999 to 2000, Ms. Carter was the Director of Business Development of Cardinal Health, Inc., a multi national health care service company. Ms. Carter earned her MBA from Wharton School of Business, University of Pennsylvania and a B.S. in Chemistry from the College of William and Mary.
- Joseph Cooper
-
Joseph Cooper，自2021年5月起担任Quoin Inc.董事。库珀先生自2021年10月28日起担任Quoin有限公司董事。Cooper先生在制药和医疗保健行业的运营、企业发展和一般管理方面拥有丰富的经验。自2012年以来，库珀先生一直担任制药和医疗保健咨询公司Boulder Cove LC的总裁。从2019年9月到2022年12月，库珀先生担任数字健康公司Resonea，Inc.的战略和企业发展主管。从2018年8月至2019年12月，库珀先生担任临床阶段制药公司NuvOx Pharmaceuticals的首席商务官。2015年1月至2018年8月，库珀先生担任非营利医疗保健服务组织First Place，AZ的首席财务和运营官。从1996年到2010年，库珀先生担任医药和医疗美容公司Medicis Pharmaceutical Corp.（纽约证券交易所代码：MRX）的企业和产品开发执行副总裁。自2018年1月起，库珀担任专业制药公司Sonoran Biosciences的董事。2006年至2007年，库珀先生担任制药公司Bioenvision（纳斯达克：BIVN）的董事。库珀拥有亚利桑那州立大学WP凯里商学院的MBA学位和东北伊利诺伊大学的学士学位。
Joseph Cooper has served as a director of Quoin Inc. since May 2021. Mr. Cooper has served as a director of Quoin Ltd. since October 28, 2021. Mr. Cooper has significant experience in finance, operation, corporate development and general management roles within the pharmaceutical and healthcare industry. Since July 2023, Mr. Cooper has served as Chief Financial Officer for Hydrinity Skin Sciences, a medical aesthetics company. From 2012 to 2023, Mr. Cooper served as the President of Boulder Cove LC, a pharmaceutical and healthcare consulting company. From September 2019 to December 2022, Mr. Cooper served as the Chief of Strategy and Corporate Development for Resonea, Inc., a digital health company. From August 2018 to December 2019, Mr. Cooper served as the Chief Business Officer of NuvOx Pharmaceuticals, a clinical stage pharmaceutical company. From January 2015 to August 2018, Mr. Cooper served as Chief Financial and Operating Officer for First Place, AZ, a non profit healthcare services organization. From 1996 to 2010, Mr. Cooper served as the Executive Vice President of Corporate and Product Development of Medicis Pharmaceutical Corp., a publicly traded pharmaceutical and medical aesthetics company. Since January 2018, Mr. Cooper has served as a director of Sonoran Biosciences, a specialty pharmaceutical company. From 2006 to 2007, Mr. Cooper served as a director of Bioenvision, a publicly traded pharmaceutical company. Mr. Cooper holds an MBA from the WP Carey School of Business at Arizona State University and a BA from Northeastern Illinois University. - Joseph Cooper，自2021年5月起担任Quoin Inc.董事。库珀先生自2021年10月28日起担任Quoin有限公司董事。Cooper先生在制药和医疗保健行业的运营、企业发展和一般管理方面拥有丰富的经验。自2012年以来，库珀先生一直担任制药和医疗保健咨询公司Boulder Cove LC的总裁。从2019年9月到2022年12月，库珀先生担任数字健康公司Resonea，Inc.的战略和企业发展主管。从2018年8月至2019年12月，库珀先生担任临床阶段制药公司NuvOx Pharmaceuticals的首席商务官。2015年1月至2018年8月，库珀先生担任非营利医疗保健服务组织First Place，AZ的首席财务和运营官。从1996年到2010年，库珀先生担任医药和医疗美容公司Medicis Pharmaceutical Corp.（纽约证券交易所代码：MRX）的企业和产品开发执行副总裁。自2018年1月起，库珀担任专业制药公司Sonoran Biosciences的董事。2006年至2007年，库珀先生担任制药公司Bioenvision（纳斯达克：BIVN）的董事。库珀拥有亚利桑那州立大学WP凯里商学院的MBA学位和东北伊利诺伊大学的学士学位。
- Joseph Cooper has served as a director of Quoin Inc. since May 2021. Mr. Cooper has served as a director of Quoin Ltd. since October 28, 2021. Mr. Cooper has significant experience in finance, operation, corporate development and general management roles within the pharmaceutical and healthcare industry. Since July 2023, Mr. Cooper has served as Chief Financial Officer for Hydrinity Skin Sciences, a medical aesthetics company. From 2012 to 2023, Mr. Cooper served as the President of Boulder Cove LC, a pharmaceutical and healthcare consulting company. From September 2019 to December 2022, Mr. Cooper served as the Chief of Strategy and Corporate Development for Resonea, Inc., a digital health company. From August 2018 to December 2019, Mr. Cooper served as the Chief Business Officer of NuvOx Pharmaceuticals, a clinical stage pharmaceutical company. From January 2015 to August 2018, Mr. Cooper served as Chief Financial and Operating Officer for First Place, AZ, a non profit healthcare services organization. From 1996 to 2010, Mr. Cooper served as the Executive Vice President of Corporate and Product Development of Medicis Pharmaceutical Corp., a publicly traded pharmaceutical and medical aesthetics company. Since January 2018, Mr. Cooper has served as a director of Sonoran Biosciences, a specialty pharmaceutical company. From 2006 to 2007, Mr. Cooper served as a director of Bioenvision, a publicly traded pharmaceutical company. Mr. Cooper holds an MBA from the WP Carey School of Business at Arizona State University and a BA from Northeastern Illinois University.
- Natalie Leong
-
Natalie Leong，自2021年4月起担任Quoin Inc.董事。梁女士自2021年10月28日起担任Quoin Ltd.董事。自2023年1月以来，梁女士一直担任BS.D. Capital，Inc.（d/b/a Lendistry）产品管理高级副总裁，这是一家由少数族裔主导的小企业贷款机构。梁女士曾担任金融SaaS公司LoanStreet Inc.的财务和产品战略主管（2019年10月– 2020年10月），随后担任产品管理主管（2020年10月– 2022年11月）。2016年5月至2019年7月，梁女士担任加拿大皇家银行资本市场美国资产负债委员会负责人。此外，从2018年8月至2019年10月，她还担任加拿大皇家银行资本市场的Global Originations FP & A主管。2011年10月至2016年5月，梁女士在澳大利亚国民银行担任Capital Insights副总裁。2008年2月至2011年10月，梁女士担任澳大利亚国民银行高级审计员。梁女士在宾夕法尼亚大学沃顿商学院获得了MBA学位。2007年，她在墨尔本大学获得了金融和经济学学士学位和文学学士学位。
Natalie Leong has served as a director of Quoin Inc. since April 2021. Ms. Leong has served as a director of Quoin Ltd. since October 28, 2021. Since January 2025, Ms. Leong has been the Managing Director of Lendistry Capital Partners, a private equity/private credit fund manager, and had been the Senior Vice President of Product Management for B.S.D. Capital, Inc. (d/b/a Lendistry), a small business originator, from January 2022 to January 2025. Ms. Leong was the Head of Finance and Product Strategy (October 2019 – October 2020) and subsequently Head of Product Management (October 2020 – November 2022) for LoanStreet Inc., a financial SaaS company. From May 2016 to July 2019, Ms. Leong served as the Lead for the Asset Liability Committee for the US at RBC Capital Markets. In addition, from August 2018 to October 2019, she served as the Lead for Global Originations FP&A for RBC Capital Markets. From October 2011 to May 2016, Ms. Leong worked as the Vice President of Capital Insights at National Australia Bank. From February 2008 to October 2011, Ms. Leong served as a Senior Auditor at National Australia Bank. Ms. Leong earned her MBA at The Wharton School, University of Pennsylvania. She earned a B.Comm degree (Finance and Economics) and a B.A. degree (French and Literature) from the University of Melbourne in 2007. - Natalie Leong，自2021年4月起担任Quoin Inc.董事。梁女士自2021年10月28日起担任Quoin Ltd.董事。自2023年1月以来，梁女士一直担任BS.D. Capital，Inc.（d/b/a Lendistry）产品管理高级副总裁，这是一家由少数族裔主导的小企业贷款机构。梁女士曾担任金融SaaS公司LoanStreet Inc.的财务和产品战略主管（2019年10月– 2020年10月），随后担任产品管理主管（2020年10月– 2022年11月）。2016年5月至2019年7月，梁女士担任加拿大皇家银行资本市场美国资产负债委员会负责人。此外，从2018年8月至2019年10月，她还担任加拿大皇家银行资本市场的Global Originations FP & A主管。2011年10月至2016年5月，梁女士在澳大利亚国民银行担任Capital Insights副总裁。2008年2月至2011年10月，梁女士担任澳大利亚国民银行高级审计员。梁女士在宾夕法尼亚大学沃顿商学院获得了MBA学位。2007年，她在墨尔本大学获得了金融和经济学学士学位和文学学士学位。
- Natalie Leong has served as a director of Quoin Inc. since April 2021. Ms. Leong has served as a director of Quoin Ltd. since October 28, 2021. Since January 2025, Ms. Leong has been the Managing Director of Lendistry Capital Partners, a private equity/private credit fund manager, and had been the Senior Vice President of Product Management for B.S.D. Capital, Inc. (d/b/a Lendistry), a small business originator, from January 2022 to January 2025. Ms. Leong was the Head of Finance and Product Strategy (October 2019 – October 2020) and subsequently Head of Product Management (October 2020 – November 2022) for LoanStreet Inc., a financial SaaS company. From May 2016 to July 2019, Ms. Leong served as the Lead for the Asset Liability Committee for the US at RBC Capital Markets. In addition, from August 2018 to October 2019, she served as the Lead for Global Originations FP&A for RBC Capital Markets. From October 2011 to May 2016, Ms. Leong worked as the Vice President of Capital Insights at National Australia Bank. From February 2008 to October 2011, Ms. Leong served as a Senior Auditor at National Australia Bank. Ms. Leong earned her MBA at The Wharton School, University of Pennsylvania. She earned a B.Comm degree (Finance and Economics) and a B.A. degree (French and Literature) from the University of Melbourne in 2007.
- Michael Sember
-
Michael Sember，自2021年5月起担任Quoin Inc.董事。森伯先生自2021年10月28日起担任Quoin有限公司董事。自2007年以来，他一直担任Accela Advisors的负责人，这是一家生物制药咨询公司，专门为初创企业提供战略规划、业务发展和指导。2018年1月至2020年10月，森伯先生担任药物开发公司Regulonix Holding，Inc.的首席执行官。从2022年到2023年，森伯担任RaeSedo，Inc的首席执行官，这是一家从亚利桑那大学分拆出来的初创治疗公司。从2015年10月到2019年3月，他担任亚利桑那大学发现的发明形成的公司的驻校导师。从2013年到2015年，森伯先生是药物输送系统公司Palyon Medical Corporation的企业转型专家和首席执行官。1991年至2002年，Sember先生担任 lan公司企业业务发展执行副总裁，负责战略合作和并购。1973年至1991年，森伯先生在马里昂实验室（Marion Laboratories，后来的Marion Merrell Dow）担任全球项目管理高级主管。2013年至2015年，森伯先生担任药物输送系统公司Paylon Medical Corporation的董事会主席。2012年至2013年，森伯先生担任非盈利贸易组织——亚利桑那州南部生物工业组织董事会主席。森伯先生在匹兹堡大学获得理学学士学位，在罗克赫斯特大学获得MBA学位。
Michael Sember has served as a director of Quoin Inc. since May 2021. Mr. Sember has served as a director of Quoin Ltd. since October 28, 2021. Since 2007, he has served as a Principal of Accela Advisors, a biopharmaceutical consulting firm specializing in strategic planning, business development and coaching for startups. From 2022 until 2023, Mr. Sember served as the Interim Chief Executive Officer of RaeSedo, Inc, a startup therapeutics company spun out of the University of Arizona. From January 2018 to October 2020, Mr. Sember served as the Interim Chief Executive Officer of Regulonix Holding, Inc., a drug development company. From October 2015 to March 2019, he served as the Mentor in Residence to companies formed from inventions discovered at the University of Arizona. From 2013 to 2015, Mr. Sember was the Corporate Turnaround Specialist and Chief Executive Officer of Palyon Medical Corporation, a drug delivery system company. From 1991 to 2002, Mr. Sember was Executive Vice President of Corporate Business Development for lan Corporation, responsible for strategic collaborations and mergers and acquisitions. From 1973 to 1991, Mr. Sember served as the Senior director of Global Program Management at Marion Laboratories (later Marion Merrell Dow). From 2013 to 2015, Mr. Sember was the Chairman of the Board of Palyon Medical Corporation, a drug delivery system company. From 2012 to 2013, Mr. Sember was the Chairman of the Board of BioIndustry Organization of Southern Arizona, a non profit trade group. Mr. Sember earned a Bachelor of Science degree from the University of Pittsburgh and an MBA from Rockhurst University. - Michael Sember，自2021年5月起担任Quoin Inc.董事。森伯先生自2021年10月28日起担任Quoin有限公司董事。自2007年以来，他一直担任Accela Advisors的负责人，这是一家生物制药咨询公司，专门为初创企业提供战略规划、业务发展和指导。2018年1月至2020年10月，森伯先生担任药物开发公司Regulonix Holding，Inc.的首席执行官。从2022年到2023年，森伯担任RaeSedo，Inc的首席执行官，这是一家从亚利桑那大学分拆出来的初创治疗公司。从2015年10月到2019年3月，他担任亚利桑那大学发现的发明形成的公司的驻校导师。从2013年到2015年，森伯先生是药物输送系统公司Palyon Medical Corporation的企业转型专家和首席执行官。1991年至2002年，Sember先生担任 lan公司企业业务发展执行副总裁，负责战略合作和并购。1973年至1991年，森伯先生在马里昂实验室（Marion Laboratories，后来的Marion Merrell Dow）担任全球项目管理高级主管。2013年至2015年，森伯先生担任药物输送系统公司Paylon Medical Corporation的董事会主席。2012年至2013年，森伯先生担任非盈利贸易组织——亚利桑那州南部生物工业组织董事会主席。森伯先生在匹兹堡大学获得理学学士学位，在罗克赫斯特大学获得MBA学位。
- Michael Sember has served as a director of Quoin Inc. since May 2021. Mr. Sember has served as a director of Quoin Ltd. since October 28, 2021. Since 2007, he has served as a Principal of Accela Advisors, a biopharmaceutical consulting firm specializing in strategic planning, business development and coaching for startups. From 2022 until 2023, Mr. Sember served as the Interim Chief Executive Officer of RaeSedo, Inc, a startup therapeutics company spun out of the University of Arizona. From January 2018 to October 2020, Mr. Sember served as the Interim Chief Executive Officer of Regulonix Holding, Inc., a drug development company. From October 2015 to March 2019, he served as the Mentor in Residence to companies formed from inventions discovered at the University of Arizona. From 2013 to 2015, Mr. Sember was the Corporate Turnaround Specialist and Chief Executive Officer of Palyon Medical Corporation, a drug delivery system company. From 1991 to 2002, Mr. Sember was Executive Vice President of Corporate Business Development for lan Corporation, responsible for strategic collaborations and mergers and acquisitions. From 1973 to 1991, Mr. Sember served as the Senior director of Global Program Management at Marion Laboratories (later Marion Merrell Dow). From 2013 to 2015, Mr. Sember was the Chairman of the Board of Palyon Medical Corporation, a drug delivery system company. From 2012 to 2013, Mr. Sember was the Chairman of the Board of BioIndustry Organization of Southern Arizona, a non profit trade group. Mr. Sember earned a Bachelor of Science degree from the University of Pittsburgh and an MBA from Rockhurst University.
- James Culverwell
-
James Culverwell，自2021年4月起担任Quoin Inc.的董事。Culverwell先生自2021年10月28日起担任Quoin Ltd.的董事。自2013年5月起，Culverwell先生担任首席执行官，目前担任前列腺癌研究公司HOX Therapeutics的董事会主席。2005年，Culverwell先生创立了Sudbrook Associates，该公司为生命科学公司提供战略建议和资金筹集服务。1992年至2004年，Culverwell先生担任美林证券高级副总裁兼全球协调人医疗保健研究。1982年至1992年，Culverwell先生担任私人银行公司ABN Amro Bank N.V。的医疗保健股票研究主管。自2022年2月起，Culverwell先生担任TC BioPharm（控股）有限公司的董事和审计委员会主席，该公司是一家上市公司和一家癌症治疗开发公司。自2005年1月起，Culverwell先生担任高通量分子诊断公司SafeGuard Biosystems的董事、审计委员会主席、薪酬委员会成员。2016年4月至2019年9月，Culverwell先生担任Amryt Pharma PLC的董事和审计委员会主席，该公司是一家上市公司和商业阶段的生物制药公司。2013年2月至2017年7月，Culverwell先生担任Innocoll AG的董事和审计委员会主席。他以优异的成绩获得了阿伯丁大学的理学硕士学位。
James Culverwell has served as a director of Quoin Inc. since April 2021. Mr. Culverwell has served as a director of Quoin Ltd. since October 28, 2021. Since May 2013, Mr. Culverwell has served as the Chief Executive Officer and is currently Chairman of the Board of Directors of HOX Therapeutics, a prostate cancer research company. In 2005, Mr. Culverwell founded Sudbrook Associates, which provided strategic advice and fund raising services for life science companies. From 1992 to 2004, Mr. Culverwell was Senior Vice President and Global Coordinator Healthcare Research at Merrill Lynch. From 1982 to 1992, Mr. Culverwell was Director of Healthcare Equity Research at ABN Amro Bank N.V., a global investment bank. From February 2022 until October 2025, Mr. Culverwell served as a director and Audit Committee Chairman of TC BioPharm (Holdings) plc, a publicly traded company and a cancer treatment development company. From January 2005 until January 2026, Mr. Culverwell served as a director, Audit Committee Chairman, and member of the Compensation Committee of SafeGuard Biosystems, a high throughput molecular diagnostics company. From April 2016 to September 2019, Mr. Culverwell served as a director and Audit Committee Chairman of Amryt Pharma PLC, a publicly traded company and a commercial stage biopharmaceutical company. From February 2013 to July 2017, Mr. Culverwell served as a director and Audit Committee Chairman of Innocoll AG. He received an MSc with honors from the University of Aberdeen. - James Culverwell，自2021年4月起担任Quoin Inc.的董事。Culverwell先生自2021年10月28日起担任Quoin Ltd.的董事。自2013年5月起，Culverwell先生担任首席执行官，目前担任前列腺癌研究公司HOX Therapeutics的董事会主席。2005年，Culverwell先生创立了Sudbrook Associates，该公司为生命科学公司提供战略建议和资金筹集服务。1992年至2004年，Culverwell先生担任美林证券高级副总裁兼全球协调人医疗保健研究。1982年至1992年，Culverwell先生担任私人银行公司ABN Amro Bank N.V。的医疗保健股票研究主管。自2022年2月起，Culverwell先生担任TC BioPharm（控股）有限公司的董事和审计委员会主席，该公司是一家上市公司和一家癌症治疗开发公司。自2005年1月起，Culverwell先生担任高通量分子诊断公司SafeGuard Biosystems的董事、审计委员会主席、薪酬委员会成员。2016年4月至2019年9月，Culverwell先生担任Amryt Pharma PLC的董事和审计委员会主席，该公司是一家上市公司和商业阶段的生物制药公司。2013年2月至2017年7月，Culverwell先生担任Innocoll AG的董事和审计委员会主席。他以优异的成绩获得了阿伯丁大学的理学硕士学位。
- James Culverwell has served as a director of Quoin Inc. since April 2021. Mr. Culverwell has served as a director of Quoin Ltd. since October 28, 2021. Since May 2013, Mr. Culverwell has served as the Chief Executive Officer and is currently Chairman of the Board of Directors of HOX Therapeutics, a prostate cancer research company. In 2005, Mr. Culverwell founded Sudbrook Associates, which provided strategic advice and fund raising services for life science companies. From 1992 to 2004, Mr. Culverwell was Senior Vice President and Global Coordinator Healthcare Research at Merrill Lynch. From 1982 to 1992, Mr. Culverwell was Director of Healthcare Equity Research at ABN Amro Bank N.V., a global investment bank. From February 2022 until October 2025, Mr. Culverwell served as a director and Audit Committee Chairman of TC BioPharm (Holdings) plc, a publicly traded company and a cancer treatment development company. From January 2005 until January 2026, Mr. Culverwell served as a director, Audit Committee Chairman, and member of the Compensation Committee of SafeGuard Biosystems, a high throughput molecular diagnostics company. From April 2016 to September 2019, Mr. Culverwell served as a director and Audit Committee Chairman of Amryt Pharma PLC, a publicly traded company and a commercial stage biopharmaceutical company. From February 2013 to July 2017, Mr. Culverwell served as a director and Audit Committee Chairman of Innocoll AG. He received an MSc with honors from the University of Aberdeen.
高管简历
中英对照 | 中文 | 英文- Sally Lawlor
Sally Lawlor，拥有20年的上市和私营公司经验和财务领导角色，以及“四大”会计师事务所。Lawlor女士曾在Sebela Pharmaceuticals Inc.担任集团税务高级总监（2023年1月至2025年8月）和集团税务总监（2021年12月至2023年1月），Sebela Pharmaceuticals Inc.是一家提供胃肠道疾病治疗方案并专注于女性健康创新的制药公司。最近在Sebela Pharmaceuticals任职期间，Lawlor女士根据美国公认会计原则和国际财务报告准则管理财务报告，监督全球税务规划和合规，以及预算编制、预测和外部审计。在加入Sebela之前，从2017年12月到2021年9月，Lawlor女士曾在Aptiv Plc担任高级税务领导职务，该公司是一家全球技术公司，设计、开发和制造软件和硬件解决方案，以实现更安全、更环保和更互联的移动出行未来。在此之前，Lawlor女士在毕马威会计师事务所工作了11年，主要为制药和技术领域的跨国客户提供咨询服务。Lawlor女士是爱尔兰特许会计师协会的会员，也是爱尔兰税务学会的成员。
Sally Lawlor has served as Chief Financial Officer of Quoin Ltd. since August 18, 2025 and has 20 years of experience in financial leadership roles in public and private companies as well as a "Big Four" accounting firm. Ms. Lawlor served as both Senior Director — Group Tax (from January 2023 through August 2025) and Director — Group Tax (December 2021 through January 2023) at Sebela Pharmaceuticals Inc., a pharmaceutical company delivering therapeutic options for gastrointestinal diseases and with a focus on innovation in women's health. In her most recent role at Sebela Pharmaceuticals, Ms. Lawlor managed financial reporting under U.S. GAAP and IFRS, oversaw global tax planning and compliance, as well as budgeting, forecasting, and external audits. Prior to Sebela, from December 2017 through September 2021, Ms. Lawlor served in senior tax leadership positions at Aptiv Plc, a global technology company that designs, develops and manufactures software and hardware solutions to enable a safer, greener and more connected future of mobility. Prior thereto, Ms. Lawlor spent eleven years at KPMG advising multinational clients, primarily in the pharmaceutical and technology sectors. Ms. Lawlor is a Fellow of Chartered Accountants Ireland and a member of the Irish Taxation Institute. She earned her Bachelor of Common Law from University College Cork. Ms. Lawlor is the niece of Dr. Michael Myers, the Company's Chairman and Chief Executive Officer.- Sally Lawlor，拥有20年的上市和私营公司经验和财务领导角色，以及“四大”会计师事务所。Lawlor女士曾在Sebela Pharmaceuticals Inc.担任集团税务高级总监（2023年1月至2025年8月）和集团税务总监（2021年12月至2023年1月），Sebela Pharmaceuticals Inc.是一家提供胃肠道疾病治疗方案并专注于女性健康创新的制药公司。最近在Sebela Pharmaceuticals任职期间，Lawlor女士根据美国公认会计原则和国际财务报告准则管理财务报告，监督全球税务规划和合规，以及预算编制、预测和外部审计。在加入Sebela之前，从2017年12月到2021年9月，Lawlor女士曾在Aptiv Plc担任高级税务领导职务，该公司是一家全球技术公司，设计、开发和制造软件和硬件解决方案，以实现更安全、更环保和更互联的移动出行未来。在此之前，Lawlor女士在毕马威会计师事务所工作了11年，主要为制药和技术领域的跨国客户提供咨询服务。Lawlor女士是爱尔兰特许会计师协会的会员，也是爱尔兰税务学会的成员。
- Sally Lawlor has served as Chief Financial Officer of Quoin Ltd. since August 18, 2025 and has 20 years of experience in financial leadership roles in public and private companies as well as a "Big Four" accounting firm. Ms. Lawlor served as both Senior Director — Group Tax (from January 2023 through August 2025) and Director — Group Tax (December 2021 through January 2023) at Sebela Pharmaceuticals Inc., a pharmaceutical company delivering therapeutic options for gastrointestinal diseases and with a focus on innovation in women's health. In her most recent role at Sebela Pharmaceuticals, Ms. Lawlor managed financial reporting under U.S. GAAP and IFRS, oversaw global tax planning and compliance, as well as budgeting, forecasting, and external audits. Prior to Sebela, from December 2017 through September 2021, Ms. Lawlor served in senior tax leadership positions at Aptiv Plc, a global technology company that designs, develops and manufactures software and hardware solutions to enable a safer, greener and more connected future of mobility. Prior thereto, Ms. Lawlor spent eleven years at KPMG advising multinational clients, primarily in the pharmaceutical and technology sectors. Ms. Lawlor is a Fellow of Chartered Accountants Ireland and a member of the Irish Taxation Institute. She earned her Bachelor of Common Law from University College Cork. Ms. Lawlor is the niece of Dr. Michael Myers, the Company's Chairman and Chief Executive Officer.
- Michael Myers
Michael Myers是特拉华州公司、Quoin Ltd（简称“Quoin Inc.”）的全资子公司Quoin制药的联合创始人，自Quoin Inc.于2018年成立以来一直担任该公司的董事长兼首席执行官。Myers博士自2021年10月28日起担任Quoin Ltd.董事长兼首席执行官。Myers博士在药物输送和专业制药领域拥有超过35年的行业经验。2003年至2015年10月，他担任生物治疗制药公司Innocoll AG（n/k/a Innocoll Biotherapeutics N.A. Inc.）的首席执行官，并负责该公司于2014年上市。2001年至2002年，他担任West Pharmaceutical Services, Inc.（纽约证券交易所代码：WST）药物输送部门的总裁，该公司是注射药物包装和输送系统的设计者和制造商。从1996年到1999年，迈尔斯博士担任食品和药物输送系统和技术开发商Fuisz Technologies（Biovail）的制药业务总裁。2000年至2001年，迈尔斯博士担任Flamel Technologies（n/k/a Avadel制药 PLC（纳斯达克：AVDL））的执行副总裁兼首席商务官，这是一家专业制药公司。从1987年到1995年，迈尔斯博士担任生物技术制药公司Elan公司的药物开发主管。从2022年到2023年6月，迈尔斯博士担任Ethicann Pharmaceuticals和SquareX Pharmaceuticals的董事，这两家公司都是一家处于临床阶段的制药公司。2023年8月，迈尔斯博士成为临床前阶段医疗设备公司Cranial Devices Inc.的董事。自2019年以来，迈尔斯博士一直担任Sonoran Bioscience和Wellesley Pharmaceuticals的董事，这两家公司都是一家专业制药公司。迈尔斯博士在爱尔兰科克大学学院获得化学博士学位。
Michael Myers is the co founder of Quoin Inc. and has served as Chairman and Chief Executive Officer of Quoin Pharmaceuticals, Inc. ("Quoin Inc.") since its inception in 2018. Dr. Myers has served as Chairman and Chief Executive Officer of Quoin Ltd. since October 28, 2021. Dr. Myers has over 36 years of industry experience in the drug delivery and specialty pharmaceutical sectors. From 2003 to October 2015, he served as Chief Executive Officer of Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), a biotherapeutics pharmaceutical company, and was responsible for taking that company public in 2014. From 2001 to 2002, he served as President of the drug delivery division of West Pharmaceutical Services, Inc., a publicly traded company and a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. From 1996 to 1999, Dr. Myers served as the President of Pharmaceutical Operations for Fuisz Technologies (Biovail), a developer of food and drug delivery systems and technologies. From 2000 to 2001, Dr. Myers served as Executive Vice President and Chief Commercial Officer of Flamel Technologies (n/k/a Avadel Pharmaceuticals PLC, a publicly traded company and a specialty pharmaceutical company). From 1987 to 1995, Dr. Myers served as the Head of Pharmaceutical Development for Elan Corporation, a biotechnology drug company. Since 2019, Dr. Myers has served as a director of Sonoran Bioscience and Wellesley Pharmaceuticals, each a specialty pharmaceutical company. Dr. Myers has served as a director of Cranial Devices, a clinical stage medical device company since 2023. Dr. Myers earned his Ph.D. in Chemistry from University College Cork, Ireland.- Michael Myers是特拉华州公司、Quoin Ltd（简称“Quoin Inc.”）的全资子公司Quoin制药的联合创始人，自Quoin Inc.于2018年成立以来一直担任该公司的董事长兼首席执行官。Myers博士自2021年10月28日起担任Quoin Ltd.董事长兼首席执行官。Myers博士在药物输送和专业制药领域拥有超过35年的行业经验。2003年至2015年10月，他担任生物治疗制药公司Innocoll AG（n/k/a Innocoll Biotherapeutics N.A. Inc.）的首席执行官，并负责该公司于2014年上市。2001年至2002年，他担任West Pharmaceutical Services, Inc.（纽约证券交易所代码：WST）药物输送部门的总裁，该公司是注射药物包装和输送系统的设计者和制造商。从1996年到1999年，迈尔斯博士担任食品和药物输送系统和技术开发商Fuisz Technologies（Biovail）的制药业务总裁。2000年至2001年，迈尔斯博士担任Flamel Technologies（n/k/a Avadel制药 PLC（纳斯达克：AVDL））的执行副总裁兼首席商务官，这是一家专业制药公司。从1987年到1995年，迈尔斯博士担任生物技术制药公司Elan公司的药物开发主管。从2022年到2023年6月，迈尔斯博士担任Ethicann Pharmaceuticals和SquareX Pharmaceuticals的董事，这两家公司都是一家处于临床阶段的制药公司。2023年8月，迈尔斯博士成为临床前阶段医疗设备公司Cranial Devices Inc.的董事。自2019年以来，迈尔斯博士一直担任Sonoran Bioscience和Wellesley Pharmaceuticals的董事，这两家公司都是一家专业制药公司。迈尔斯博士在爱尔兰科克大学学院获得化学博士学位。
- Michael Myers is the co founder of Quoin Inc. and has served as Chairman and Chief Executive Officer of Quoin Pharmaceuticals, Inc. ("Quoin Inc.") since its inception in 2018. Dr. Myers has served as Chairman and Chief Executive Officer of Quoin Ltd. since October 28, 2021. Dr. Myers has over 36 years of industry experience in the drug delivery and specialty pharmaceutical sectors. From 2003 to October 2015, he served as Chief Executive Officer of Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), a biotherapeutics pharmaceutical company, and was responsible for taking that company public in 2014. From 2001 to 2002, he served as President of the drug delivery division of West Pharmaceutical Services, Inc., a publicly traded company and a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. From 1996 to 1999, Dr. Myers served as the President of Pharmaceutical Operations for Fuisz Technologies (Biovail), a developer of food and drug delivery systems and technologies. From 2000 to 2001, Dr. Myers served as Executive Vice President and Chief Commercial Officer of Flamel Technologies (n/k/a Avadel Pharmaceuticals PLC, a publicly traded company and a specialty pharmaceutical company). From 1987 to 1995, Dr. Myers served as the Head of Pharmaceutical Development for Elan Corporation, a biotechnology drug company. Since 2019, Dr. Myers has served as a director of Sonoran Bioscience and Wellesley Pharmaceuticals, each a specialty pharmaceutical company. Dr. Myers has served as a director of Cranial Devices, a clinical stage medical device company since 2023. Dr. Myers earned his Ph.D. in Chemistry from University College Cork, Ireland.
- Denise Carter
Denise Carter是Quoin Inc.的联合创始人，自2018年成立以来一直担任Quoin Inc.的董事和首席运营官。卡特女士自2021年10月28日起担任Quoin Ltd.的董事和首席运营官。Denise Carter女士在药物输送和专业制药行业拥有超过30年的经验。2003年6月至2015年10月，Carter女士在Innocoll AG（n/k/a Innocoll Biotherapeutics N.A. Inc.）担任多个职位，包括Innocoll Pharmaceuticals总裁和Innocoll AG业务发展和公司事务执行副总裁。2001年至2003年，卡特女士担任西药公司（纽约证券交易所代码：WST）药物输送部门的业务发展副总裁。2000年至2001年，她担任专业制药公司Eurand的业务发展高级总监。1996年至1999年，卡特女士担任Fuisz Technologies（Biovail）业务发展和联盟管理总监。1999年至2000年，卡特女士担任卡地纳健康集团业务发展总监，这是一家跨国医疗保健服务公司。卡特在宾夕法尼亚大学沃顿商学院获得MBA学位，在威廉玛丽学院获得化学学士学位。
Denise Carter is the co founder of Quoin Inc. and has served as a director and Chief Operating Officer of Quoin Inc. since its inception in 2018. Ms. Carter has served as a director and Chief Operating Officer of Quoin Ltd. since October 28, 2021. Ms. Denise Carter has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. From June 2003 to October 2015, Ms. Carter held various positions at Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), including President of Innocoll Pharmaceuticals and Executive Vice President of Business Development and Corporate Affairs of Innocoll AG. From 2001 to 2003, Ms. Carter was the Vice President of Business Development of the drug delivery division of West Pharmaceuticals, Inc., a publicly traded company. From 2000 to 2001, she was the Senior Director of Business Development of Eurand, a specialty pharmaceutical company. From 1996 to 1999, Ms. Carter was the Director of Business Development and Alliance Management of Fuisz Technologies (Biovail). From 1999 to 2000, Ms. Carter was the Director of Business Development of Cardinal Health, Inc., a multi national health care service company. Ms. Carter earned her MBA from Wharton School of Business, University of Pennsylvania and a B.S. in Chemistry from the College of William and Mary.- Denise Carter是Quoin Inc.的联合创始人，自2018年成立以来一直担任Quoin Inc.的董事和首席运营官。卡特女士自2021年10月28日起担任Quoin Ltd.的董事和首席运营官。Denise Carter女士在药物输送和专业制药行业拥有超过30年的经验。2003年6月至2015年10月，Carter女士在Innocoll AG（n/k/a Innocoll Biotherapeutics N.A. Inc.）担任多个职位，包括Innocoll Pharmaceuticals总裁和Innocoll AG业务发展和公司事务执行副总裁。2001年至2003年，卡特女士担任西药公司（纽约证券交易所代码：WST）药物输送部门的业务发展副总裁。2000年至2001年，她担任专业制药公司Eurand的业务发展高级总监。1996年至1999年，卡特女士担任Fuisz Technologies（Biovail）业务发展和联盟管理总监。1999年至2000年，卡特女士担任卡地纳健康集团业务发展总监，这是一家跨国医疗保健服务公司。卡特在宾夕法尼亚大学沃顿商学院获得MBA学位，在威廉玛丽学院获得化学学士学位。
- Denise Carter is the co founder of Quoin Inc. and has served as a director and Chief Operating Officer of Quoin Inc. since its inception in 2018. Ms. Carter has served as a director and Chief Operating Officer of Quoin Ltd. since October 28, 2021. Ms. Denise Carter has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. From June 2003 to October 2015, Ms. Carter held various positions at Innocoll AG (n/k/a Innocoll Biotherapeutics N.A. Inc.), including President of Innocoll Pharmaceuticals and Executive Vice President of Business Development and Corporate Affairs of Innocoll AG. From 2001 to 2003, Ms. Carter was the Vice President of Business Development of the drug delivery division of West Pharmaceuticals, Inc., a publicly traded company. From 2000 to 2001, she was the Senior Director of Business Development of Eurand, a specialty pharmaceutical company. From 1996 to 1999, Ms. Carter was the Director of Business Development and Alliance Management of Fuisz Technologies (Biovail). From 1999 to 2000, Ms. Carter was the Director of Business Development of Cardinal Health, Inc., a multi national health care service company. Ms. Carter earned her MBA from Wharton School of Business, University of Pennsylvania and a B.S. in Chemistry from the College of William and Mary.